PGR and carcinoma: We subdivided the carcinoma case into 3 molecular subtypes: luminal (ER and/or PR positive, HER2 ±), HER2 enriched (ER and PR negative, HER2 positive), and triple-negative (ER, PR, and HER2 all negative).